What is the diagnosis and appropriate initial management for a patient with total iron‑binding capacity 410 µg/dL, serum iron 26 µg/dL, transferrin saturation 6 %, ferritin 19 ng/mL, hemoglobin 12.2 g/dL, mean corpuscular hemoglobin 24.9 pg, mean corpuscular hemoglobin concentration 31.4 g/dL, red cell distribution width 16.8 %, and mean corpuscular volume 79 fL?

Iron Deficiency Anemia: Diagnosis and Management

This patient has absolute iron deficiency anemia requiring oral iron supplementation and mandatory investigation for the underlying cause of iron loss. 1

Diagnostic Interpretation

Your laboratory values unequivocally confirm iron deficiency anemia:

• Transferrin saturation of 6% falls well below the diagnostic threshold of 16% for adults, confirming absolute iron deficiency 1, 2
• Ferritin 19 ng/mL is below 30 ng/mL, which has 100% specificity for depleted iron stores in the absence of inflammation 1
• Elevated TIBC (410 µg/dL) reflects compensatory upregulation of transferrin production when body iron stores are empty 1, 2
• Hemoglobin 12.2 g/dL meets criteria for anemia in adult females (normal ≥12 g/dL) 1
• MCV 79 fL indicates microcytosis, though more than 50% of iron-deficient patients have normal MCV 1
• Elevated RDW (16.8%) reveals the heterogeneous red cell population characteristic of iron deficiency 1

The combination of low serum iron (26 µg/dL), elevated TIBC (410 µg/dL), and transferrin saturation <16% definitively establishes absolute iron deficiency requiring treatment. 1

Mandatory Evaluation for Underlying Cause

Iron deficiency never occurs without an identifiable source of loss or inadequate intake. 1 You must investigate:

Gastrointestinal Investigation (Highest Priority)

• In postmenopausal women or men, gastrointestinal evaluation is mandatory to exclude malignancy 1
• Upper and lower endoscopy are recommended; dual pathology occurs in roughly 10% of cases 1
• Upper endoscopy identifies a causative lesion in 30–50% of evaluated patients 1
• Small-bowel biopsies during endoscopy detect celiac disease in 2–3% of patients with iron deficiency anemia 1
• Stool guaiac testing should be performed 1

Menstrual Assessment (If Premenopausal)

• Heavy menstrual bleeding is defined as soaking through a pad or tampon every 1–2 hours or periods lasting >7 days 1
• However, severe or refractory anemia should not be attributed solely to menstrual blood loss without comprehensive evaluation 1

Additional Considerations

• Dietary history: Assess for low heme iron intake, especially in vegetarian/vegan diets 1
• Medication review: NSAIDs, aspirin, anticoagulants causing occult GI bleeding 1
• Malabsorption: Celiac disease serologic screening (anti-endomysial antibody) if endoscopy cannot be performed 1
• Blood donation or high-impact athletic activity causing hemolysis 1

First-Line Treatment: Oral Iron

Standard oral iron preparations contain the following elemental iron per 325 mg tablet: 1

• Ferrous sulfate: 65 mg elemental iron
• Ferrous gluconate: 38 mg elemental iron
• Ferrous fumarate: 106 mg elemental iron

Dosing Strategy

• Alternate-day dosing (every other day) markedly improves fractional iron absorption compared with daily dosing, which raises hepcidin and blocks subsequent uptake 1
• Administer on an empty stomach (≥1 hour before or ≥2 hours after meals) to maximize absorption 1
• Reduce elemental iron dose to 50–100 mg per administration; higher doses do not increase absorption and increase gastrointestinal side effects 1

Expected Response

• Hemoglobin should increase by 1–2 g/dL within 4–8 weeks of adequate therapy 1, 3
• If no response occurs after 4–8 weeks despite adherence, switch to intravenous iron 1

Treatment Targets

• Hemoglobin ≥12 g/dL in adult females 1
• Ferritin ≥50 ng/mL (in absence of inflammation) 1
• Transferrin saturation ≥20% to ensure sufficient iron for erythropoiesis 1, 2

Indications for Switching to Intravenous Iron

Switch to IV iron if any of the following occur: 1

• Gastrointestinal intolerance (nausea, constipation, diarrhea)
• Lack of hematologic response after 4–8 weeks of adequate oral therapy
• Chronic kidney disease with eGFR <30 mL/min/1.73 m²
• Documented malabsorption (celiac disease, inflammatory bowel disease, post-bariatric surgery)
• Ongoing blood loss exceeding oral replacement capacity

IV Iron Formulations 1, 4

Formulation	Maximum Single Dose	Special Considerations
Ferric carboxymaltose	1,000 mg	Rapid administration; low hypersensitivity risk
Ferric derisomaltose	1,000 mg or 20 mg/kg (max 1,500 mg)	FDA-approved for total-dose infusion
Iron sucrose	200 mg	No test dose required
Low-molecular-weight iron dextran	High-dose infusion	Requires test dose due to anaphylaxis risk

Monitoring Schedule

• Repeat iron studies 4–8 weeks after completing oral iron course or after the last IV iron infusion 1, 2
• Do not measure iron parameters within 4 weeks of IV iron infusion, as circulating iron falsely elevates results 1, 2

Critical Diagnostic Pitfalls to Avoid

• Do not rely on "normal" serum iron (26 µg/dL) to exclude deficiency—serum iron shows high day-to-day variability and is affected by meals, diurnal changes, and inflammation 1
• Do not delay gastrointestinal investigation when iron deficiency is identified in men or postmenopausal women 1
• Do not continue oral iron indefinitely without reassessment; lack of response after 4–8 weeks warrants evaluation for malabsorption, ongoing loss, or transition to IV iron 1
• Do not obtain iron studies too early after IV iron (within 4 weeks) to avoid misleadingly elevated values 1, 2

Additional Laboratory Considerations

• Measure C-reactive protein to identify subclinical inflammation that could affect ferritin interpretation 1
• Calculate estimated glomerular filtration rate to assess for chronic kidney disease 1
• Obtain complete blood count with reticulocyte count to evaluate bone marrow response 1